Capable of transforming iron into magnetic nano-treasures, these microorganisms form a diverse group of prokaryotes known as magnetotactic bacteria (MTB), recognized for their unique ability to biomineralize magnetic particles (called magnetosomes) inside the cell. These membrane-bound magnetic crystals, typically arranged in chain-like structures, enable passive alignment along geomagnetic fields, a phenomenon known as magnetotaxis [1, 2]. In recent years, magnetic nanoparticles (MNPs) have gained significant attention due to their applicability in various biotechnological and medical domains, including drug delivery, cancer theranostics, imaging, biosensing, catalysis, and bioseparation [2–4]. However, synthetic MNPs face limitations in clinical use, particularly due to concerns about biocompatibility, toxicity, and functional instability [5]. This review investigates the potential of magnetotactic bacteria-derived nanoparticles (MTB-NPs) as superior alternatives to synthetic MNPs. Due to their natural origin, MTB-NPs exhibit enhanced biocompatibility, reduced immunogenicity, greater functional stability, and sustainability, making them highly attractive for targeted biomedical applications. We conducted a comparative analysis of recent literature, focusing on the mechanisms through which MTB contribute as personalized tools in biomedical applications. Furthermore, we propose an integrative conceptual framework that bridges existing empirical evidence with future directions for clinical translation. The novelty of our approach lies in the synthesis of the most recent data, the identification of current research gaps, and the structured presentation of MTB in direct opposition to their synthetic counterparts (magnetic nanoparticles) in terms of quality, sustainability, biocompatibility, and efficiency in biomedical and biotechnological applications.